Respiratory failure & ventilation
Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial
Primary result · Heterogeneity of treatment effect on 28-day mortalityResult — go to the resultOdds ratio 0.17 95% CI 0.07–0.40Authors' conclusion
Overall, treatment effect with vilobelimab was consistent across different classes and subtypes, except for the δ subtype, suggesting potential additional benefit for the most severely ill patients.
Study context
- Population
- Mechanically ventilated COVID-19 patients in the PANAMO trial
- Participants
- 368 participants
- Comparison
- Vilobelimab (C5a inhibitor) treatment effect across latent classes and clinical sepsis subtypes
- Class 1n = 82
- Class 2n = 286
- αn = 41
- βn = 17
- δn = 112
- γn = 198
- Primary endpoint
- 28-day mortality
- Follow-up
- 28 days
Methodological detailspost hoc, phase 3, unsupervised learning (latent class analysis (LCA), hierarchical clustering, clinical sepsis subtypes)
- Post hoc
- Phase 3
- Unsupervised learning (LCA, hierarchical clustering, clinical sepsis subtypes)
Primary result
As reported in the abstract
Heterogeneity of treatment effect on 28-day mortality
Odds ratio
0.17
95% CI 0.07–0.40
P < 0.001
δ
OR 0.17 (95% CI 0.07–0.40); P < 0.001
- No heterogeneity of treatment effect (HTE) between LCA classes (adjusted logistic regression)
- P = 0.998
- No significant classes with hierarchical clustering
- P = 0.669
- HTE between clinical subtypes
- P = 0.001
Safety
Harm of vilobelimab
- No signal for harm in any class or clinical subtype
Original publication
Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial. Crit Care. Published 28 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →